LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: REGN) ("Regeneron"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has inked a five-year collaboration deal with Zoetis Inc. (NYSE: ZTS), which is a global animal health Company. The deal is aimed at researching the use of Regeneron's monoclonal antibody therapeutics in animals, and discover new veterinary treatments. The financial details of the deal remained undisclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Regeneron Pharma and Zoetis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=REGN

www.active-investors.com/registration-sg/?symbol=ZTS

Terms of the Collaboration Deal

  • Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which the latter will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. The focused areas will be allergic and immune-related conditions, pain, inflammatory diseases, and cancer.
  • Regeneron will receive a license fee, approval and sales milestone payments, and royalties on any potential veterinary treatments.
  • Regeneron will also select antibodies from its pipeline for Zoetis to evaluate in dogs and cats that have certain naturally-occurring diseases, such as osteoarthritis. The data generated using this approach can help provide valuable information for potential new veterinary therapeutics.

VelocImmune® is Regeneron's proprietary technology in which the immune system of mice is genetically humanized, enabling the creation of fully-human and optimized antibody drug candidates.

Collaboration Extends Valuable Tools to Development of Monoclonal Antibodies Modified for Species-Specific Use in Animals

Drew Murphy, Ph.D., Senior Vice President of Research at Regeneron, stated that the Company's VelociSuite® drug discovery and development platforms have produced many important new medicines for people with serious medical conditions. Murphy added that this collaboration extends these valuable tools to the development of monoclonal antibodies modified for species-specific use in animals, an area Regeneron would not be exploring otherwise, and provides it with more information to develop safe and efficacious medicines for humans.

Deal will Enhance Zoetis' Internally-Developed Pipeline of Novel Monoclonal Antibodies

Commenting on the collaboration, Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, mentioned that the Company sees significant advantages from Zoetis and Regeneron scientists sharing knowledge and know-how across animal and human health. Knupp added that this collaboration will enhance Zoetis' internally-developed pipeline of novel monoclonal antibodies and hasten the development of therapeutics that could transform the way veterinarians treat a range of diseases in animals.

About Regeneron Pharmaceuticals, Inc.

Founded in 1988 and based in Tarrytown, New York, Regeneron is a leading biotechnology organization that invents life-transforming medicines for people with serious diseases. Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies to yield optimized fully-human antibodies, and ambitious initiatives.

About Zoetis Inc.

Headquartered in Parsippany, New Jersey, Zoetis is a global animal health Company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, it delivers quality medicines and vaccines, complemented by diagnostic products, genetic tests, bio-devices, and a range of services.

Stock Performance Snapshot

June 07, 2018 - At Thursday's closing bell, Regeneron Pharma's stock declined 2.03%, ending the trading session at $308.72.

Volume traded for the day: 826.29 thousand shares.

Stock performance in the last month ? up 8.00%

After yesterday's close, Regeneron Pharma's market cap was at $32.01 billion.

Price to Earnings (P/E) ratio was at 20.40.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you?re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

SOURCE: Active-Investors